Celgene Adds Antibody to Multiple Myeloma Pipeline with MorphoSys Deal
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 12 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1964 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
After out-licensing its mid-stage rheumatoid arthritis drug candidate MOR103 to GlaxoSmithKline earlier in June 2013, MorphoSys has secured Celgene as a global co-development and commercialisation partner for its CD38-targeted human monoclonal antibody MOR202, which is in Phase I/IIa development for relapsed/refractory multiple myeloma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS